FDA reviews psychiatric side effects of popular anti-smoking drug

By: Associated Press
By: Associated Press
The Food and Drug Administration announced Friday it will convene a public meeting in October to review the risks of psychiatric and behavioral side effects with Pfizer

MGN Online

WASHINGTON The Food and Drug Administration announced Friday it will convene a public meeting in October to review the risks of psychiatric and behavioral side effects with Pfizer's anti-smoking drug Chantix.

The agency says in a federal notice it will convene its panel of psychiatric drug experts to discuss the pill's risks and how to manage them.

Since 2009 Chantix has carried the government's strongest safety warning due to links to hostility, agitation, depression and suicidal thoughts. The warning was added after the FDA received dozens of reports of suicide and suicidal behavior among patients taking Chantix.

At that time the FDA also required Pfizer to conduct additional studies.

A spokeswoman for Pfizer said Friday that the company recently submitted new data to the FDA designed to show the drug's safety.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
WNDU - Channel 16 54516 State Road 933 South Bend, IN 46637 Front Desk: 574-284-3000 Newsroom: 574-284-3016 Email: newscenter16@wndu.com
Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 256700221 - wndu.com/a?a=256700221
Gray Television, Inc.